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ABSTRACT 
BRIANNA GODLEWSKI  The linkage between HPA axis dysregulation and 
metabolic syndrome.  Department of Biological Sciences, June 2017. 
 
ADVISOR: Brian Cohen 
 A diagnosis of Metabolic Syndrome (MSX) requires patients to present with three 
or more of the following symptoms: elevated fasting blood glucose levels, elevated serum 
triglyceride levels, low serum HDL levels, elevated blood pressure, and truncal obesity. 
This pathology shares many similarities with Cushing’s Syndrome (CS) but a diagnosis 
of CS requires hypercortisolemia. This similarity has led our lab and others to 
hypothesize that MSX may be a Cushingoid-like state caused by hypersensitivity of the 
glucocorticoid receptor (GR), a nuclear hormone receptor that is activated when cortisol 
binds, and or hyperactivity of the enzyme 11beta-hydroxysteroid dehydrogenase (11β-
HSD) type 1, the cortisol reductase enzyme. The 11β-HSD1 enzyme is responsible for 
the conversion of inactive cortisone to cortisol, and works primarily in the adipose tissue. 
Using an allele specific polymerase chain reaction (PCR) protocol, previous research in 
our lab has found significant correlations between the BclI and N363S polymorphisms of 
the glucocorticoid receptor and altered patient metabolic profiles in a population of 
patients seeking bariatric surgery, suggesting their possible contribution to diseases such 
as obesity and Metabolic Syndrome.   
Recent work within our lab has found that the frequency of the single nucleotide 
polymorphism rs12086634, the hyperactivity polymorphism of interest within the 11β-
HSD1 enzyme, is 23.9% for our obese population and only 14.1% for our random college 
population. This suggests that this polymorphism may contribute to increased obesity and 
the MSX metabolic profile by increasing the localized cortisol in adipose tissue.   
Additionally, our lab has expanded our study to include the cortisol resistance 
polymorphism TthIIIi (rs10052957) to test the hypothesis that there would be a decreased 
prevalence of this polymorphism in our subject population.  The TthIIIi allele is present 
at 1.7% frequency in an obese population and at 6.94% frequency in a random college 
population. 
Greater understanding of the interplay between these single nucleotide polymorphisms 
can help physicians and patients make more informed decisions about treatment options 
for obesity and metabolic syndrome. 
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Introduction 
 
 The hypothalamic-pituitary-adrenal (HPA) axis is a highly controlled central 
component of the neuroendocrine system1.  When activated, primarily by stress, the HPA 
axis is responsible for restoring homeostasis to the body through a signaling pathway that 
begins in the brain1.  When stress is detected, corticotropin releasing hormone (CRH) is 
released from the hypothalamus and travel to the anterior pituitary where it binds to the 
adrenocorticotropic hormone (ACTH) receptor1.  ACTH is then released from the 
anterior pituitary and targets the glucocorticoid receptor in the adrenal cortex, specifically 
the zona fasciculata, signaling for the release of glucocorticoids (GCs), which in humans 
is mainly cortisol1. 
GCs are extremely diverse 
molecules with different functions 
in each part of the body.  Cortisol, 
the main GC in humans, plays an 
important role in 
immunosuppression, anti-
inflammatory action, growth, brain 
functioning, and most importantly 
glucose and lipid metabolism2.  
Cortisol’s activity is mediated by 
the GC receptor.  As a steroid hormone derived from cholesterol, cortisol is able to cross 
the plasma membrane and bind to its receptor in the cytoplasm of almost all cells in the 
body.  The receptor is part of the nuclear receptor family due to its ability to enter the 
Figure	1	HPA	Axis.	
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nucleus when cortisol is bound and the receptor is activated2.  Once in the nucleus the 
activated complex acts as a transcription factor to control gene expression2.   
Cortisol’s control of gene expression plays a role in important metabolic, 
cardiovascular, immune, and psychological functioning3.  Cortisol has been shown to 
increase low-density lipoprotein (LDL) circulation, but not high-density lipoprotein 
(HDL) circulation, thus resulting in an increase in triglycerides3.  Cortisol is also known 
for its role in fat accumulation, specifically in the abdominal region3.  Additionally, 
cortisol has been indicated to raise blood pressure3.  These functions, all mediated by 
cortisol, present an interesting avenue of study: cortisol’s effect on obesity. 
Obesity is an epidemic affecting more than 34.9% of the population, which 
translates to more than 78.6 million Americans4. Obesity is defined in adults as an 
individual with a body mass index (BMI) greater than or equal to 30, with BMI being 
calculated by dividing weight in kilograms (kg) by height in meters squared (m^2). This 
large proportion of the population has an increased risk of heart disease, stroke, type 2 
diabetes, and certain types of cancer4. Because of the higher prevalence of these 
conditions within this population, we, as a nation, spend $1,429 more on healthcare per 
obese person compared to those of normal weight, which totals to $147 billion in obesity 
related medical expenses4. The alarming number of obese, and the costs that are 
associated with them, makes obesity an important public health problem to investigate.  
Parallel to the increase in obesity has been an increase in bariatric surgery5.  There are 
three main types of bariatric surgery: Roux-en- Y gastric bypass, the sleeve gastrectomy, 
and the adjustable gastric band.  Bariatric surgery is a known and highly recommended 
solution for those suffering from morbid obesity and its associated comorbidities.   
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 A subset of the obese population suffers from Cushing’s Syndrome.  Cushing’s 
Syndrome is characterized by high levels of cortisol, whether endogenous or exogenous6.  
Typical physical representations of the syndrome include obesity, moon face, buffalo 
hump, thin skin, poor wound healing, purple striae, effects on libido and menstruation, 
hirsutism, and a range of psychiatric symptoms, including depression6.  This range of 
symptoms is a result of the vast number of tissues that contain the GR. 
An additional subset of the obese population suffers from a syndrome extremely 
similar to Cushing’s Syndrome, but lack the corresponding hormone levels.  Metabolic 
Syndrome (MSX) is known as a syndrome of elimination.  It is characterized by a 
complex group of symptoms, that together make up a MSX diagnosis.  A diagnosis 
requires a patient to present with at least three of these five symptoms: high fasting blood 
glucose, high blood pressure, abdominal obesity, high triglyceride levels, and low HDL 
cholesterol levels7.  How is it possible that these two syndromes can so closely resemble 
one another but have such different hormone panels?  
Single-nucleotide polymorphisms (variations in the DNA sequence) (SNPs) 
within the gene for the cortisol receptor (GR) and/or within the genes that encode the 
11beta-hydroxysteroid dehydrogenase type 1 (11β-HSD1) enzyme, may contribute to 
Figure	2	Comparisons	between	MSX	and	Cushing's	Syndrome.	
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obesity in general, and the similarities observed between MSX and Cushing’s.  By 
increasing cortisol sensitivity within the GR, identical symptoms to Cushing’s Syndrome 
can be observed without the elevated levels of cortisol.  BclI (located within the intron 2, 
647 base pairs from the exon/intron junction) 8, and N363S (where the amino acid 
asparagine normally found at position 363 in the protein sequence is changed to the 
amino acid serine) 9 are two of the most studied SNPs causing hypersensitivity of the GR.  
Both are known to cause the GR to over respond to normal, or even low, levels of 
cortisol, thus producing the appearance of symptoms that coincide with high levels of 
cortisol.  Additionally, Tthlll1 (a C to T change 6305 base pairs upstream of the first 
initiation codon), a known resistance polymorphism, has made its way into several 
studies examining the effects of SNPs on obesity3.  Although a resistance polymorphism 
does not seem to make sense in an obesity study investigating how low to normal levels 
of cortisol can produce a phenotype similar to that produced by high levels of cortisol, 
several studies have seen interesting results when combinations of SNPs are present. 
Figure	3	GR	with	noteworthy	SNPs.	
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In addition to SNPs within the GR, SNPs within the enzyme 11β-HSD1, cause an 
increase in localized cortisol concentrations.  The 11β-HSD enzyme is found in two 
forms throughout the body and is responsible for the conversion of inactive cortisone and 
cortisol10.  The type 2 enzyme converts active cortisol to inactive cortisone, while the 
type 1 enzyme converts inactive cortisone to active cortisol10.  The type 1 enzyme is of 
particular interest when studying obesity due to its expression within adipose tissue.  Two 
SNPs of particular interest are rs1208663411,12 and rs84691011.  Both are polymorphisms 
within the genes encoding for 11β-HSD1 enzyme that result in over-activity11,12.  Over-
activity of the 11β-HSD1 enzyme results in over-conversion of inactive cortisone to 
active cortisol, thus causing increased localized cortisol concentrations.  Specifically, 
within adipose tissue, this is detrimental and can contribute to the physical manifestation 
of truncal obesity. 
The purpose of our study was to compare the prevalence of these SNPs within the 
GR and the genes that encode the enzyme 11β-HSD1 within an obese, bariatric 
population compared to a normal weight population comprised of college students.  
Additionally, we are interested in how these SNPs and/or combination of these SNPs 
Figure	4	Conversion	of	cortisol	to	cortisone	and	vise	versa	via	the	11β-HSD1	enzyme.	
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correspond with metabolic parameters of our obese population.  Finally, we wish to 
investigate the correlation between these SNPs and/or combination of these SNPs and 
success of bariatric surgery, as defined by weight lost and weight re-gained.  By studying 
these SNPs and their influence on a bariatric population, personalized decisions following 
genotyping can be made to ensure greater success in the treatment of the ever-expanding 
obese population. 
Methods 
Data Collection 
Buccal samples 
were collected from 35 
patients at the Ellis 
Bariatric Center, 
Schenectady, NY, along 
with medical information 
and several metabolic 
parameters: height, original 
weight, pre-surgery weight, type of surgery and date completed, lowest weight, current 
weight, blood pressure, serum triglycerides, low density lipoprotein cholesterol, high 
density lipoprotein cholesterol, and blood glucose levels.  Ellis Hospital’s Institutional 
Review Board approved sample collection for two years (Appendix A).  Patients were 
given an informed consent that iterated the purpose of the study and what information we 
would be collecting from the online record system (Appendix B).  Buccal samples were 
also collected from 44 undergraduate students at Union College, Schenectady, NY.  
Figure	5	General	overview	of	the	procedure. 
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Students were given an informed consent and were asked to provide their height, weight, 
and whether they had ever been diagnosed with depression (Appendix C).  Following the 
informed consent, both sets of participants were given a 10mL centrifuge tube with sterile 
saline.  Participants were asked to swish the liquid around their mouths for approximately 
ten seconds and then empty their mouth into a small plastic cup.  The contents were then 
transferred from the plastic cup back to the centrifuge tube carefully and were labeled.  
Both the Ellis patients and undergraduate students were known by their medical record 
number or their sample number for the remainder of the study in order to maintain patient 
privacy and anonymity.  The tubes were then stored in the lab freezer until DNA 
extraction. 
DNA Isolation 
DNA was isolated using a chelex bead protocol that is detailed in Appendix D. 
Allele Specific PCR 
 In order to complete 
polymerase chain reaction on 
the DNA that had been isolated 
from our patient samples, allele 
specific primers were needed.  
Sequences for our target SNP’s 
were gathered from the 
literature.  Then, using a Web-Based Allele Specific Primer (WASP) program, we 
designed allele specific primers for each SNP in question.  The WASP program gave us 
several different primer options for each SNP, and based upon melting temperatures we 
Figure	6	Functioning	primer	sets. 
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were able to select what we thought would be the most successful primer set.  Each 
primer set included a common primer, a wild type primer, and a mutant primer.  The wild 
type primer would only bind if the wild type sequence was present, but not if the mutant 
sequence was present, and vise versa with the mutant primer.  This allowed us to 
genotype patients.  Based upon the melting temperatures provided by the WASP 
program, we were able to begin the process of primer optimization for the new SNPs our 
lab was investigating.  This involved using gradients to determine the temperature that 
yielded the most specific banding.  In some cases Q solution was used or changing of the 
magnesium concentrations.  Ultimately two additional primer sets were optimized for 
rs12086634 and Tthlll1.  Optimal conditions for our functioning primer sets can be seen 
in Table 1.  PCR was run on participant samples using these optimized conditions. 
Table	1	Optimized	conditions	for	functioning	primer	sets.	
 
Gel Electrophoresis 
 PCR products were analyzed by electrophoresis on a 2.5% agarose gel at 
approximately 130 V for 30 to 40 minutes.  Prior to loading the gel, ethidium bromide 
was loaded into the buffer on the right side of the gel box and to the gel itself before it 
had solidified.  This allowed the DNA to move down the gel depending on size and to be 
Polymorphism PCR	contents Template	Concentration Annealing	Temp With	 or	without	Q BcI1 1	μl	buffer,	1	μl	common	primer,	1	μl	WT	or	MU	primer,	0.5	μl	dNTPs,	0.5	μl	taq,	34	μl	H20 8	μl 52° w/o N363 1	μl	buffer,	1	μl	common	primer,	1	μl	WT	or	MU	primer,	0.5	μl	dNTPs,	0.5	μl	taq,	34	μl	H20 8	μl 55° w/o RS12086634 1	μl	buffer,	1	μl	common	primer,	1	μl	WT	or	MU	primer,	0.5	μl	dNTPs,	0.5	μl	taq,	34	μl	H20 8	μl 51° w/o TthIII1 1	μl	buffer,	1	μl	common	primer,	1	μl	WT	or	MU	primer,	0.5	μl	dNTPs,	0.5	μl	taq,	34	μl	H20 8	μl 61° w/o 
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seen under UV light following the completion of the DNA migration.  The visualization 
of bands under UV light allowed us to genotype patients and determine the frequency of 
the mutant alleles within our two populations. 
Data Analysis 
 Mutant allele frequencies were calculated by adding the percentage of the 
population with a mutant genotype and the half the percentage of the population with a 
heterozygote genotype.  The percentages of the population were calculated by dividing 
the number of people with each genotype by the total population of successful tests. 
Results 
 As described previously our data analysis consisted of calculating and comparing 
mutant allele frequencies.  These results are listed in Table 2.  For BclI, our obese sample 
population size was 79 and our random undergraduate population size was 43.  The 
mutant allele frequency for the bariatric population was 39.2%, while the mutant allele 
frequency of the random population was 31.4%.  The N363S bariatric population size 
was 54 and the random population size was 41.  The mutant allele frequency for the 
Figure	7	Example	of	gels	ran	for	patients	25,	26,	27,	28,	29,	and	31	for	each	of	the	optimized	primer	sets. 
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bariatric population was 4.6% and for the random population was 4.9%.  The Tthlll1 
bariatric population size was 29 and the random population size was 36.  The mutant 
allele frequency of the bariatric population was 1.7% and within the random population 
was 6.94%.  The bariatric population size for rs12086634 was 23 and was 32 for the 
random population.  The mutant allele frequency for the bariatric population was 23.9% 
and was 14.1% for the random population. 
Table	2	Results	of	sample	testing	for	BclI,	N363S,	Tthlll1,	and	rs12086634. 	
 Gene	Polymorphism Genotype	Frequency Allele	Frequency 
Name Name 
Phenotype	of	
mutant 
Random	
population 
Bariatric 
population 
Random	
population 
Bariatric	
population 
WT Hetero MT n WT Hetero MT n WT MT WT MT 
GR 
RS41423247	
(BclI) 
Hypersensitivity	
to	cortisol 47 44.2 9.3 43 37 48.1 15 79 68.6 31.4 60.8 39.2 
GR 
RS6195	
(N363S) 
Hypersensitivity	
to	cortisol 93 4.9 2.4 41 91 9.3 0 54 95.1 4.9 95.4 4.6 
GR 
RS10052957	
(TthIII1) 
Resistance	to	
cortisol 92 2.8 5.6 36 97 3.4 0 29 93.1 6.94 98.3 1.7 
11b-
HSD	
Type	1 RS12086634 Type	II	Diabetes 75 21.9 3.1 32 61 30.4 8.7 23 85.9 14.1 76.1 23.9 
 
Discussion 
Findings 
 In our study, we hypothesized that MSX was a cushingoid-like state caused by 
hypersensitivity of the GR and or hyperactivity of the enzyme 11β-HSD1.  Because of 
this we expected to find unique mutant gene frequencies within our bariatric population 
when compared to a random undergraduate population. 
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 Prior to genotyping, we expected our bariatric population to have a larger mutant 
allele frequency for BclI, N363S, and rs12086634 than our random population.  
Additionally, we hypothesized the Tthlll1 mutant allele would appear less frequently in 
our bariatric population when compared to our random population.  As seen in our 
results, these hypotheses were mostly supported by our data.  BclI had a higher mutant 
allele frequency within the bariatric population than the random population.  This was 
also true for rs12086634 as well.  Tthlll1 had a much lower mutant allele frequency in the 
bariatric population than in the random population. 
 However, one piece of data we did not expect to see was the high mutant allele 
frequency for N363S within the random population.  While the bariatric population and 
the random undergraduate population had essentially the same mutant allele frequency, 
according to dpsnp, an online database that compiles information about known SNPs, the 
expected mutant allele frequency for a random population is around 1.15%13.  This was 
not supported by our data, and our hypothesis for N363S was ultimately not supported. 
Limitations 
 One of the biggest limitations of this study was our sample size.  Our lab was only 
able to collect samples when we were physically present at Ellis Bariatric Center; there 
were no samples collected on our behalf by the nurses or the staff of the center.  
Additionally, patients some patients denied our request for a buccal sample.  While this 
did not happen often, there were few occasions where the patient did not feel comfortable 
participating.  Furthermore, the current procedure for DNA collection and isolation is 
effective, but not always successful.  For some of our participants there was an extremely 
limited amount of DNA actually contained within the sample.  This made performing the 
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PCR reactions difficult for these samples.  Finally, there was occasional PCR error and 
the PCR conditions would just not give us results.  This cut our sample population and 
reduced the sample size, especially for rs12086634 and Tthlll1, which did not have 
previous year’s research to build off of. 
Additionally, another limitation of this study is our reliance on BMI as an accurate 
measure of obesity.  BMI is one of the quickest and easiest ways to classify someone as 
underweight, normal weight, overweight, obese, or morbidly obese.  However, this 
formula does not take into account some extremely important factors such as muscle 
content.  There are much better measures of obesity such as body fat content, waist 
circumference, and waist to hip ration, but these methods are slower and often more 
expensive. 
Directions for Future Research 
 Primarily we would like to continue our statistical analysis of our current data, 
and complete haplotype analyses.  But, our first avenue of true future research is to 
continue to collect samples for this study.  In order to establish clinical significance, we 
need a much larger patient population, and this is one of the major long-term goals of our 
laboratory.  Also, by collecting more samples, we increase the likelihood that we have 
patients who are five to ten years post-surgery.  Collecting samples from this population 
will allow us to continue to study the success of each type of surgery as defined by 
weight regain.  With a large enough patient population we can begin to see trends in the 
types of surgeries that work best for those who has the single nucleotide polymorphisms. 
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In addition to collecting more samples, developing a new more reliable protocol 
for sample collection is a priority.  Using cotton swabs versus a saline wash could aid in 
the collection of cheek cells, which is ultimately what we gather DNA from. 
 Adding additional SNPs, in combination with the existing SNPs we have been 
studying, will allow us to cover a broad range of mutations that exist within the GR and 
the enzyme 11β-HSD1.  Three such SNPs, which we have discovered in the literature, are 
rs7701443 and rs2963156 within the GR, and rs846910 within 11β-HSD1. 
 Furthermore, upon studying the hyperactivity polymorphisms within 11β-HSD1, 
this lead us to examine what else large amounts of cortisol can do within the body in 
addition to metabolic effects.  One such effect is on the mineralocorticoid receptor (MR).  
When there is excess cortisol, due to the similarity between the structures of aldosterone 
and cortisol, the MR can be activated.  Having both the GR and the MR activated at the 
same time may cause interesting and unforeseen affects within the body.  Additionally, 
there are known SNPs within the MR itself that may effect this even more significantly. 
Finally, we wish to use similar methods in order to study HPA axis dysregulation and its 
affects on clinical depression.  HPA axis dysregulation has been implicated as one of the 
possible causes of clinical depression, as we saw in the possible clinical manifestations of 
Cushing’s Syndrome.  By examining SNPs indicated in the literature, we will begin to 
collect samples from patients with depression in partnership with Albany Medical 
College.  We will use the same PCR and gel electrophoresis techniques to examine the 
frequencies of indicated SNPs within this new population. 
Clinical Significance 
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 Personalized medicine is the future.  Within every field, researchers and scientists 
are looking to give patients an individualized approach to treatment that diminishes side 
effects and increases success of treatment.  This is the long-term goal of our study.  
Because of the patient population we are studying, we have begun to notice as our patient 
population has grown, that when a patient is homozygous mutant or heterozygous for the 
polymorphisms we are investigating they are more susceptible to weight regain following 
certain types of surgery.  This was observed by Sebastian Gingras, a former member of 
our lab, specifically with the adjustable gastric band.  Ultimately, having the ability to 
screen our patients for a panel of SNPs, we will be able to formulate an exact treatment 
plan and recommend the best possible type of surgery for their genetic makeup.  This 
would reduce the risk of weight regain and eliminate unnecessary risk for patients. 
Conclusion 
   Obesity is an epidemic that has not only been plaguing the United States, but the 
world as a whole.  In fact, the World Health Organization (WHO) estimates that since 
1980 worldwide obesity has doubled14.  In addition to the growing number of obese, we 
also see a growing number of those suffering from the comorbidities of obesity, 
specifically heart disease and diabetes15.  This is a problem we need to be devoting time, 
resources, and research to, particularly the role of the HPA axis.  As this study has 
shown, the HPA axis and dysregulation of it may have implications in the development 
of obesity, MSX especially.  If there is indeed a genetic component to the development of 
obesity and obesity-related syndromes such as MSX, then physicians can be better 
prepared to recommend treatments following genetic screenings.  This will ultimately 
help patients suffering from this disease lose the weight and keep the weight off, as well 
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as reduce the obesity epidemic as a whole.  Fighting the epidemic will not only help the 
lives of millions, but will also ultimately reduce the costs our health care system has had 
to shoulder. 
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Appendix A 
 
 
1101 Nott Street    Schenectady, New York 
12308   
Phone: (518) 243-
4011    www.ellismedicine.org 
 
 
December 23, 2014 
 
 
Anne Jones RN 
Brian D Cohen PhD 
Ellis Medicine Bariatric Care Center 
2125 River Road Suite #302 
Niskayuna, NY 12309 
 
Re:  Prevalence of Glucocorticoid Receptor Polymorphisms in Morbidly Obese Patients 
 
Dear Ann and Dr. Cohen 
 
Thank you for  attending the December  18, 2014 meeting of the Institutional Review 
Board. Under full board review the protocol, informed consent (with changes) and other 
materials presented for the above mentioned study were approved.  The study was 
approved for 2 years with an interim report due at the  June 2015 IRB meeting.  As a 
reminder, no additional changes may be made to this project without first submitting the 
changes to the IRB for review.  Any inquiries or unanticipated problems must also be 
promptly reported. 
 
Thank you for your continued interest in medical research. 
 
Sincerely, 
 
Michael V. Pasquarella 
 
Michael V. Pasquarella Pharm.D., R.Ph. 
Chairperson 
Institutional Review Board 
 
cc: Pat Biggica 
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Appendix B Informed	Consent	Form 
 The	 purpose	 of	 this	 research	 project	 is	 to	 look	 for	 a	 correlation	 between	polymorphisms	 of	 the	 glucocorticoid	 receptor	 (variations	 in	 the	DNA	 sequence	 of	the	natural	receptor	for	the	hormone	cortisol),	the	enzyme	11-Beta	Hydroxysteroid	Dehydrogenase	 (11-βHSD	 1)	 (the	 enzyme	 responsible	 for	 converting	 inactive	cortisone	 to	 its	 active	 form	 cortisol),	 and	 clinical	 manifestations	 of	 obesity	 and	related	 comorbidities;	 elevated	 blood	 sugar,	 blood	 pressure,	 increased	 waist/hip	circumference	 ratio,	 and	 altered	 serum	 lipid	 profiles.	 	We	 have	 previously	 been	screening	 for	 two	 hypersensitivity	 polymorphisms,	 but	 we	 will	 be	 adding	 two	additional	 polymorphisms	 within	 the	 glucocorticoid	 receptor	 as	 well	 as	 two	polymorphisms	within	the	enzyme	11-βHSD	1. 
 Agreeing	 to	participate	 in	 this	 study	means	 that	you	will	allow	 the	 testing	of	your	DNA	 for	 the	 purposes	 of	 identifying	 receptor	 variations	 and	 you	 are	 agreeing	 for	relevant	 medical	 data	 to	 be	 provided	 to	 the	 researchers	 to	 compare	 with	 the`	receptor	variations.	You	will	not	receive	 information	about	your	 individual	results	from	this	study.		Your	DNA	will	not	be	used	for	any	other	purpose	or	analyzed	in	any	other	way.		After	2	years,	your	DNA	sample	will	be	destroyed. 
 Your	decision	about	whether	or	not	to	participate	will	not	affect	your	treatment	by	Ellis	Bariatric	Medicine.	 	You	will	not	be	compensated	for	your	participation	in	the	study. 
 If	you	decide	to	participate	you	will	be	asked	to	perform	a	mouthwash	with	sterile	saline	that	will	allow	us	to	recover	cells	from	inside	your	cheek.	 	Some	people	find	the	salty	taste	of	the	saline	wash	a	little	unpleasant	but	should	provide	no	significant	discomfort	or	risk	for	you.	 
 Identification	of	which	genetic	variant(s)	of	this	gene	you	have	will	not	affect	your	treatment	 in	any	way.	 	As	 information	 is	 gathered	about	 the	 relationship	between	variations	of	 the	 cortisol	 receptor	 gene	 and	obesity	 (and	 related	diseases),	 it	may	eventually	help	identify	opportunities	for	complimentary	therapies	for	obesity,	but	this	is	beyond	the	scope	of	the	present	study.		Currently	we	are	strictly	interested	in	determining	if	 there	 is	a	connection	between	these	genes	and	obesity	(and	related	comorbidities)	and	any	discovery	will	not	affect	your	treatment	plan. 
 Your	DNA	sample	will	be	coded	with	your	patient	identification	number	instead	of	your	name	before	it	is	given	to	researchers	at	Union	College	for	DNA	analysis.		The	researchers	will	also	be	given	access	anonymously	to	relevant	medical	information	from	your	records	required	to	complete	the	study.	 	Records	given	to	Union	College	researchers	will	 only	 have	 your	 patient	 ID	 number	 and	 not	 your	 name.	 	Relevant	medical	information	will	include	but	not	strictly	be	limited	to: 
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1. Your	weight	before	you	began	treatment	2. Your	height	3. Your	waist	to	hip	ratio	or	waist	circumference	(where	available)	before	you	began	treatment	4. Fasting	blood	sugar	5. Serum	triglycerides	6. Serum	LDL	and	HDL	7. Blood	pressure	8. Related	medications	that	you	are	taking	that	might	affect	these	measures	9. Treatments	 you	 receive	 at	 Ellis	 Bariatric	 such	 as	medications	 and	 surgical	procedures	
 Your	DNA	sample	will	be	kept	in	the	laboratory	of	Dr.	Brian	Cohen	at	Union	College	and	will	 only	 be	 accessible	 to	 him	 or	 to	 his	 student	 researchers	 working	 on	 this	research	 project.	 Similarly,	 relevant	 medical	 information	 made	 available	 to	 Dr.	Cohen	 will	 only	 be	 available	 to	 him	 or	 his	 student	 researchers	 and	 will	 not	 be	accessible	to	anyone	else	at	Union	College.		 
 Although	we	do	not	anticipate	making	any	discoveries	that	would	alter	your	care	or	cause	 you	 to	wish	 to	 drop	 out	 of	 the	 study,	 if	 any	 such	 discoveries	 are	made	 the	medical	staff	of	Ellis	Bariatric	will	contact	you	and	give	you	the	option	to	withdraw	from	the	study.		Choosing	to	withdraw	from	the	study	will	in	no	way	affect	your	care	as	a	patient	of	Ellis	Bariatric.	 	We	anticipate	 that	more	 than	100	patients	will	be	a	part	of	the	study	and	the	more	patients	that	are	included,	the	more	significant	any	findings	will	be.		 
 If	you	have	any	questions,	please	ask	Anne	Jones,	RN,	CBN,	at	Ellis	Bariatric	or	Dr.	Brian	Cohen,	Union	College.	Their	contact	information	can	be	found	below.		You	will	be	asked	to	sign	one	copy	of	this	informed	consent	form	and	will	be	given	a	copy	to	keep	for	your	records. 
 The	choice	to	be	in	this	study	and	to	stay	in	this	study	is	strictly	voluntary.		Refusal	to	 participate	will	 involve	 no	 penalty	 or	 loss	 of	 benefits	which	 you	 are	 otherwise	entitled.	You	may	discontinue	your	participation	at	any	time	with	no	penalty	or	loss	of	benefits	which	you	are	otherwise	entitled.		If	you	wish	to	leave	the	study,	please	contact	 	Ms.	 Anne	 Jones	 and	 inform	 her	 that	 you	 wish	 to	 withdraw	 from	 the	study.		You	will	be	asked	to	sign	a	written	form	indicating	your	desire	to	withdraw.	Ellis	Bariatric	will	then	inform	Dr.	Cohen	of	your	ID	number	and	your	DNA	sample	will	be	destroyed	and	your	relevant	medical	information	will	be	removed	from	the	data	set. 
 Thank	 you	 for	 considering	 being	 a	 part	 of	 this	 research	 study.	 	If	 you	 have	 any	questions	before	participating	or	at	any	time	during	the	study,	please	do	not	hesitate	to	contact	us. 
 
 
HPA	Axis	Dysregulation	and	MSX	 	 		
	 21	
	
 Anne	Jones,	RN,	CBN Ellis	Bariatric	Medicine jonesa@ellismedicine.org 518-831-7030 Brian	D.	Cohen,	PhD Union	College cohenb@union.edu 518-388-8018	
 
 Michael	Pasquarella,	PharmD,	RPh Chair,	Institutional	Review	Board Ellis	Hospital pasquarellam@ellismedicine.org 518-243-1818	
 
 	
 
 	
 1. I	 have	 been	 informed	 about	 the	 purpose	 of	 this	 genetic	 test	 and	experimental	research	project.		2. I	understand	that	I	will	not	receive	the	results	from	the	testing.		3. I	have	been	informed	as	to	who	may	have	access	to	my	biological	sample,	and	 that	 the	 laboratory	may	 retain	any	 leftover	 sample	until	 the	end	of	the	study,	at	which	point	it	will	be	destroyed.		4. I	 have	 read	 the	 material	 provided	 and	 this	 consent	 form	 in	 full.	 My	questions	have	been	answered	to	my	satisfaction.		5. I	 consent	 to	 provide	 a	 sample	 for	 genetic	 testing	 and	 to	 have	 relevant	medical	data	provided	anonymously	to	the	researchers.		6. I	 understand	 that	 my	 participation	 is	 completely	 voluntary	 and	 I	 may	withdraw	 at	 any	 time	 without	 affecting	 my	 care	 as	 a	 patient	 of	 Ellis	Bariatric.	
 ______________________________________________________________________________ 
Signature	 																																																																				Date	 	  
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Appendix C 
INFORMED CONSENT FORM 
 
Our names are Brianna Godlewski and Justin Salm and we are students at Union College 
in Schenectady, NY.  We are inviting you to participate in a research study.  Involvement 
in the study is voluntary, so you may choose to participate or not.  Participation in the 
study will not affect your grade in BIO225. Your instructor will not know if you 
have participated or not.  A description of the study is written below. 
 
Our research is interested in determining if there is a relationship between variations in 
sequences of genes associated with stress responses and the prevalence of obesity and 
depression. You will be asked to provide access to the DNA sample that you generated 
for your BIO225 lab and ask you to answer a few questions including your height and 
weight and if you have ever been diagnosed with depression.  If you choose to participate 
in the study, we will ask you to put your DNA from lab into a new tube labeled with an 
arbitrary number and also to fill out a separate form marked with the same number.  This 
will take approximately 5 minutes. There are no foreseeable risks to taking part in this 
study. If you no longer wish to continue, you have the right to withdraw from the study, 
without penalty, at any time.   
 
Your responses will be anonymous: the arbitrary number will not be connected to 
you in any way so we will not be able to identify who filled out each form or whose 
DNA is being analyzed. 
 
All DNA samples collected will be destroyed after analysis, no later than 7/1/17. 
 
By signing below, you indicate that you understand the information above, and that you 
wish to participate in this research study. 
 
 
 
____________________________     _____________________________
 _________________ 
Participant Signature    Printed Name    
 Date 
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Appendix D 
Isolation	of	Crude	Human	Genomic	DNA	samples	suitable	for	PCR		 
 
	 The	source	of	DNA	that	you	will	use	for	PCR	reactions	next	week	will	be	your	cheek	cells,	which	
will	be	obtained	by	a	sterile	saline	mouthwash.		The	cells	are	collected	by	centrifugation	and	resuspend	in	
a	solution	containing	the	resin	"Chelex",	which	binds	metal	ions	that	would	otherwise	inhibit	the	PCR	
reaction.		The	cells	are	then	lysed	by	boiling,	and	centrifuged	to	remove	cell	debris	and	the	Chelex	resin.	
The	result	is	a	crude	genomic	DNA	prep	that	is	"good"	enough	for	PCR!	 
 
You	should	have	the	following	materials	available	before	you	start: 
 
Materials: 
 
Microfuge	tubes	and	racks;	micropipettors	and	tips	 
One	15	ml	plastic	“Blue-top”	tube 
One	Non-sterile	(but	unused)	plastic	“Dixie”	cup 
One	plastic	transfer	pipette	 
Labelled	Waste	container	for	“spit”	waste 
Microfuge	tube	containing	1.2	ml	of	10%	Chelex	(labeled		“Chelex")	 
Shared	Materials: 
 
Clinical	Table-top	Centrifuge	for	pelleting	cells 
Boiling	water	baths	with	“floatie”	for	boiling	samples 
Microfuge 
 
1)		Get	a	boiling	water	bath	ready	for	use	in	step	8.		Fill	up	an	ice	bucket	halfway	using	crushed	ice	
obtained	from	the	Biology	“autoclave	room”	on	the	third	floor.		 
 
2)		Label	a	15	ml	tube	(blue-top)	with	your	initials	on	the	top	and	the	side	of	the	tube,	and	pipette	(or	
carefully	pour)	10	ml	of	sterile	saline	into	the	tube.	Label	a	new	microfuge	tube	with	your	initials,	also	on	
the	top	and	side	of	the	tube. 
 
3)		Pour	all	of	the	saline	solution	into	your	mouth	(don't	swallow	it!),	and	vigorously	swish	for	15	
seconds.		Carefully	expel	the	fluid	into	a	plastic	Dixie	cup,	and	then	pour	the	liquid	back	into	the	15	ml	
tube	and	reclose	the	cap. 
 
4)		Place	your	tube	in	a	clinical	centrifuge	balanced	against	another	tube	opposite	it	in	the	rotor.		Try	and	
fill	up	the	rotor	if	you	can	with	tubes	from	other	members	of	the	class.		Centrifuge	for	10	minutes	at	1,000	
X	g	for	10	minutes	to	pellet	the	cells. 
 
5)		After	the	spin	is	over,	use	a	transfer	pipette	to	pipette	off	as	much	of	the	supernatant	as	possible	into	
the	labeled	waste	container	(we'll	autoclave	this	later).		Pipette	off	the	liquid	so	that	the	cells	remain	with	
only	a	minimal	amount	of	liquid	(approx	200	µL).		You	might	have	to	briefly	(1	min.)	spin	the	tube	again	if	
the	cells	get	dislodged	from	the	side/bottom	of	the	tube	during	this	process.		Resuspend	the	cells	in	the	
minimal	volume	of	remaining	supernatant	by	vortexing,	and	then	transfer	the	whole	volume	using	the	
same	plastic	transfer	pipette	to	a	new,	labelled	microfuge	tube.	Vortex	this	tube	containing	the	cells	for	5-
10	seconds,	making	sure	that	there	are	no	clumps	of	cells	remaining.	 
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6)		Resuspend	the	Chelex	beads	(in	the	microfuge	tube	labeled	"10%	Chelex")	by	vortexing	for	10	
seconds.		Before	the	beads	have	had	a	chance	to	settle,	pipette	500	µL	of	Chelex	solution	into	your	
microfuge	tube	containing	the	cells.		 
 
7)		Resuspend	the	cells	in	the	Chelex	by	vortexing	for	10	seconds.	Make	sure	that	no	cell	clumps	remain.	 
 
8)		Incubate	the	microfuge	tube	containing	the	cells/Chelex	mixture	in	the	boiling	water	bath	for	10	
minutes,	using	a	plastic	"floatie".		Other	peoples'	tubes	will	also	be	boiled	at	the	same	time	in	the	water	
bath,	so	make	sure	that	your	tube	is	labelled	well! 
 
9)		Remove	the	floatie	carefully	from	the	boiling	water	bath,	take	your	tube	and	incubate	it	on	ice	for	two	
minutes.		Spin	the	tube	in	a	microfuge	(max.	speed)	for	1	minute	to	pellet	the	Chelex	and	cell	debris	to	the	
bottom	of	the	tube. 
 
10)		Using	a	200	µL	pipette,	carefully	transfer	200	µL	of	the	supernatant	(pipette	from	the	top)	to	a	new,	
labeled	(with	your	initials)	microfuge	tube.		Avoid	transferring	any	of	the	pelleted	cells	or	the	Chelex.	
Discard	the	tube	containing	the	pellet.	YOUR	PREP	IS	DONE	AT	THIS	POINT!	You	should	store	your	
genomic	DNA	in	the	fridge	in	a	labeled	box	or	tube	rack.				 
 
 
 
 
 
 
 
 
 
 
  
